A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Part of paid clinical trials in New York, New York.

Sponsor
Ludwig Institute for Cancer Research
Study ID
NCT00140855
Phase
PHASE2
Status
Terminated

Conditions

  • Synovial Sarcoma

Eligibility Criteria

Sex
ALL
Age
10 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.

Key Dates

Start date
Jun 8, 2005
Status verified
Oct 2022
Primary completion
Apr 18, 2007
Completion
Jul 1, 2007

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ipilimumab
    Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.

Primary Outcome Measure

Number of Subjects With Best Tumor Response as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST). [ Time Frame: up to 10 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10021-

Find similar trials in New York, NY

By research site
Memorial Sloan-Kettering Cancer Center· New York, NY

Related Studies